- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PAVmed Inc (PAVM)
PAVmed Inc stock price live, this page displays NASDAQ PAVM stock exchange data. View the PAVM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PAVmed Inc real time stock price chart below.
What Is the PAVmed Inc Stock Price Today?
The PAVmed Inc stock price today is 5.925.
What Is the Stock Symbol for PAVmed Inc?
The stock symbol for PAVmed Inc is "PAVM."
What Stock Exchange Does PAVmed Inc Trade On?
PAVmed Inc is listed and trades on the NASDAQ stock exchange.
Is PAVmed Inc a Good Stock to Buy?
Determining whether PAVmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PAVM quote. (ISIN: US70387R5028)
What Is the PAVmed Inc Stock Price Today?
The PAVmed Inc stock price today is 5.925.
What Is the Stock Symbol for PAVmed Inc?
The stock symbol for PAVmed Inc is "PAVM."
What Stock Exchange Does PAVmed Inc Trade On?
PAVmed Inc is listed and trades on the NASDAQ stock exchange.
Is PAVmed Inc a Good Stock to Buy?
Determining whether PAVmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PAVM quote. (ISIN: US70387R5028)
NASDAQ
Currency in USD
5.925
-0.095(-1.58%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.750
6.160
52 wk Range
3.850
28.440
PAVM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.7506.160
52 wk Range
3.85028.440
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PAVM Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
36.000
Upside
+507.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form DEF 14A PAVmed Inc For: 27 April
- Investing.com
- Form 13G PAVMED INC. For: 11 May
- Investing.com
- Form DEF 14A PAVmed Inc For: 30 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 36.000
(+507.59% Upside)
PAVmed Inc Earnings Call Summary for Q1/2026
- PAVmed completed $30M Series D preferred offering, eliminating convertible debt and improving capital structure despite 4.69% premarket decline.
- Q1 2026 GAAP net loss of $1.1M ($4.42/share) versus $18.6M profit prior year; pro forma revenue exceeds $3M quarterly with $6.5M cash.
- Company shifted from incubator to integrated portfolio model, relaunching medical device segment with dedicated personnel across technologies.
- Management targets FDA clearance for Veris implantable monitor by end-2026; projects EPS loss of $0.61/share next two quarters.
- Stock trades near 52-week low of $6, down 66% from $28.44 high; market cap $43.95M reflects investor concerns on profitability timeline.
Last Updated: 05/21/2026, 04:50 AM
Read Full TranscriptEarnings
Latest Release
May 14, 2026
EPS / Forecast
-4.42 / --
Revenue / Forecast
22K / 100K
Compare PAVM to Peers and Sector
Metrics to compare | PAVM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPAVMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −7.5x | −0.4x | |
PEG Ratio | 0.01 | −0.33 | 0.00 | |
Price/Book | 1.2x | 3.6x | 2.6x | |
Price / LTM Sales | 499.0x | 2.7x | 3.0x | |
Upside (Analyst Target) | - | 42.1% | 50.8% | |
Fair Value Upside | Unlock | 10.1% | 9.4% | Unlock |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the PAVmed (PAVM) Stock Price Today?
The PAVmed stock price today is 5.925 USD.
What Stock Exchange Does PAVmed Trade On?
PAVmed is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PAVmed?
The stock symbol for PAVmed is "PAVM."
What Is the PAVmed Market Cap?
As of today, PAVmed market cap is 42.420M USD.
What Is PAVmed's Earnings Per Share (TTM)?
The PAVmed EPS (TTM) is -29.954.
From a Technical Analysis Perspective, Is PAVM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has PAVmed Stock Split?
PAVmed has split 2 times.
How Many Employees Does PAVmed Have?
PAVmed has 41 employees.
What is the current trading status of PAVmed (PAVM)?
As of Jul 19, 2026, PAVmed (PAVM) is trading at a price of 5.925 USD, with a previous close of 6.020 USD. The stock has fluctuated within a day range of 5.750 USD to 6.160 USD, while its 52-week range spans from 3.850 USD to 28.440 USD.
What Is PAVmed (PAVM) Price Target According to Analysts?
The average 12-month price target for PAVmed is 36.000 USD, with a high estimate of 56 USD and a low estimate of 16 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +507.59% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.